<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063867</url>
  </required_header>
  <id_info>
    <org_study_id>367981</org_study_id>
    <secondary_id>UH2AT007769</secondary_id>
    <secondary_id>UH3AI113337</secondary_id>
    <nct_id>NCT02063867</nct_id>
  </id_info>
  <brief_title>Active Bathing to Eliminate Infection (ABATE Infection) Trial</brief_title>
  <acronym>ABATE</acronym>
  <official_title>Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Pilgrim Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Corporation of America (HCA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>John H. Stroger Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ABATE Infection Project is a cluster randomized trial of hospitals to compare two quality
      improvement strategies to reduce multi-drug resistant organisms and healthcare-associated
      infections in non-critical care units. The two strategies to be evaluated are:

        -  Arm 1: Routine Care Routine policy for showering/bathing

        -  Arm 2: Decolonization Use of chlorhexidine as routine soap for showering or bed bathing
           for all patients Mupirocin x 5 days if MRSA+ by history, culture, or screen

      Note that enrolled &quot;subjects&quot; represents 53 individual HCA Hospitals (representing ~190
      non-critical care units) that have been randomized.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRSA and VRE Clinical Cultures</measure>
    <time_frame>21 months</time_frame>
    <description>Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gram-negative Multi-drug Resistant Organism Clinical Cultures</measure>
    <time_frame>21 months</time_frame>
    <description>Gram-negative (GN) multi-drug resistant organism clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Bloodstream Infections</measure>
    <time_frame>21 months</time_frame>
    <description>All-cause bloodstream infections attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge. Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary Tract Infections</measure>
    <time_frame>21 months</time_frame>
    <description>Urinary tract infections attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Culture Contamination</measure>
    <time_frame>21 months</time_frame>
    <description>Blood culture contamination</description>
  </other_outcome>
  <other_outcome>
    <measure>Clostridium Difficile Infection</measure>
    <time_frame>21 months</time_frame>
    <description>Clostridium difficile Infection attributable to participating units</description>
  </other_outcome>
  <other_outcome>
    <measure>30-Day Infectious Readmissions</measure>
    <time_frame>21 months</time_frame>
    <description>30-Day Infectious Readmissions among patients in participating units</description>
  </other_outcome>
  <other_outcome>
    <measure>Emergence of Resistance to Chlorhexidine or Mupirocin</measure>
    <time_frame>21 months</time_frame>
    <description>Emergence of resistance to chlorhexidine (among MRSA and select gram-negative bacteria) or mupirocin (among MRSA) for strains isolated from participating units</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost Effectiveness</measure>
    <time_frame>21 months</time_frame>
    <description>Cost effectiveness of routine care vs decolonization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthcare Associated Infections</condition>
  <condition>Methicillin Resistant Staphylococcus Aureus</condition>
  <condition>Multi Drug Resistant Organisms</condition>
  <arm_group>
    <arm_group_label>Arm 1: Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine policy for showering or bathing non-critical care patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2: Decolonization</intervention_name>
    <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
    <arm_group_label>Arm 2: Decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All HCA hospitals that reside in the United States

          -  Note: Unit of randomization is the hospital, but the participants are hospital units

        Exclusion Criteria:

          -  Non-critical care units where chlorhexidine bathing or decolonization for MRSA+
             non-critical care patients is routine

          -  Pediatric, peri-partum, rehabilitation, psychiatry, and BMT units

          -  Units with &gt;30% cardiac or hip/knee orthopedic surgeries

          -  Unit average length of stay &lt;2 days

          -  Patients &lt;12 years-old

          -  Patients with known allergy to mupirocin or chlorhexidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Huang, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken Kleinman, ScD</last_name>
    <role>Study Director</role>
    <affiliation>University of Massachusetts, Amherst</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Septimus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Corporation of America (HCA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Hickok, MBA, RN</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Corporation of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Moody, MS</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Corporation of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Hayden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Weinstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>John Stroger Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Jernigan, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Perlin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Corporation of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Gillen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace Lee, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Harvard Pilgrim Health Care Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Hills Hospital &amp; Medical Center</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Medical Center</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blake Medical Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osceola Regional Medical Center</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palms West Hospital</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Park Medical Center</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Florida Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg General Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Hospital</name>
      <address>
        <city>Sun City Center</city>
        <state>Florida</state>
        <zip>33573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Palm Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cartersville Medical Center</name>
      <address>
        <city>Cartersville</city>
        <state>Georgia</state>
        <zip>30120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coliseum Northside Hospital</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Medical Center</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overland Park Regional Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center of Acadiana</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garden Park Medical Center</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee's Summit Medical Center</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MountainView Hospital-Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkland Medical Center</name>
      <address>
        <city>Derry</city>
        <state>New Hampshire</state>
        <zip>03038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Regional Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colleton Medical Center</name>
      <address>
        <city>Walterboro</city>
        <state>South Carolina</state>
        <zip>29488</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkridge Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkridge East Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriStar Horizon Medical Center</name>
      <address>
        <city>Dickson</city>
        <state>Tennessee</state>
        <zip>37055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hendersonville Medical Center</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Center</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Regional Medical Center</name>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <zip>78526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conroe Regional Medical Center</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corpus Christi Medical Center</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Palmas Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Medical Center of Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Colinas Medical Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingwood Medical Center</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Methodist Hospital</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rio Grande Regional Hospital</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hills Hospital</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Texsan Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Specialty and Transplant Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Stone Oak Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clear Lake Regional Medical Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timpanogos Regional Hospital</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Randolph Medical Center</name>
      <address>
        <city>Hopewell</city>
        <state>Virginia</state>
        <zip>23860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LewisGale Hospital-Alleghany</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reston Hospital Center</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chippenham Johnston Willis Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henrico Doctors' Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>April 29, 2019</results_first_submitted>
  <results_first_submitted_qc>June 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Susan Huang</investigator_full_name>
    <investigator_title>Associate Professor and Medical Director of Epidemiology and Infection Prevention</investigator_title>
  </responsible_party>
  <keyword>HAI</keyword>
  <keyword>MRSA</keyword>
  <keyword>VRE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02063867/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02063867/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Participant Flow section reflects numbers of hospitals that were enrolled in the intervention (the unit of enrollment and randomization was hospital), as well as the number of participants included in analysis, (the number of patient admissions from participating units in the enrolled hospitals), in each arm during the intervention period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Usual Care</title>
          <description>Routine policy for showering or bathing non-critical care patients</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Decolonization</title>
          <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156889"/>
                <participants group_id="P2" count="183013"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152598"/>
                <participants group_id="P2" count="180048"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4291"/>
                <participants group_id="P2" count="2965"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These numbers reflect the number of participants in the baseline period across all participating facilities enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Usual Care</title>
          <description>Routine policy for showering or bathing non-critical care patients</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Decolonization</title>
          <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156889"/>
            <count group_id="B2" value="183013"/>
            <count group_id="B3" value="339902"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="18.2"/>
                    <measurement group_id="B2" value="62.6" spread="18.6"/>
                    <measurement group_id="B3" value="62.4" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Data not available for 32 patients during the intervention period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156873"/>
                    <count group_id="B2" value="182997"/>
                    <count group_id="B3" value="339870"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84585"/>
                    <measurement group_id="B2" value="100249"/>
                    <measurement group_id="B3" value="184834"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72288"/>
                    <measurement group_id="B2" value="82748"/>
                    <measurement group_id="B3" value="155036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107261"/>
                    <measurement group_id="B2" value="112067"/>
                    <measurement group_id="B3" value="219328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22581"/>
                    <measurement group_id="B2" value="38704"/>
                    <measurement group_id="B3" value="61285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21501"/>
                    <measurement group_id="B2" value="22462"/>
                    <measurement group_id="B3" value="43963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2021"/>
                    <measurement group_id="B2" value="4175"/>
                    <measurement group_id="B3" value="6196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3525"/>
                    <measurement group_id="B2" value="5605"/>
                    <measurement group_id="B3" value="9130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156889"/>
                    <count group_id="B2" value="183013"/>
                    <count group_id="B3" value="339902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156889"/>
                    <measurement group_id="B2" value="183013"/>
                    <measurement group_id="B3" value="339902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRSA and VRE Clinical Cultures</title>
        <description>Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>MRSA and VRE Clinical Cultures</title>
          <description>Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
          <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio (Intervention vs Baseline)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156889"/>
                <count group_id="O2" value="183013"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.79" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.73" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gram-negative Multi-drug Resistant Organism Clinical Cultures</title>
        <description>Gram-negative (GN) multi-drug resistant organism clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>Gram-negative Multi-drug Resistant Organism Clinical Cultures</title>
          <description>Gram-negative (GN) multi-drug resistant organism clinical cultures attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
          <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio (Intervention vs Baseline)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156889"/>
                <count group_id="O2" value="183013"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.72" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.82" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Bloodstream Infections</title>
        <description>All-cause bloodstream infections attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge. Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Bloodstream Infections</title>
          <description>All-cause bloodstream infections attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge. Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.</description>
          <population>Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156889"/>
                <count group_id="O2" value="183013"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.85" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.80" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urinary Tract Infections</title>
        <description>Urinary tract infections attributable to participating units. Defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Culture Contamination</title>
        <description>Blood culture contamination</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clostridium Difficile Infection</title>
        <description>Clostridium difficile Infection attributable to participating units</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>30-Day Infectious Readmissions</title>
        <description>30-Day Infectious Readmissions among patients in participating units</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Emergence of Resistance to Chlorhexidine or Mupirocin</title>
        <description>Emergence of resistance to chlorhexidine (among MRSA and select gram-negative bacteria) or mupirocin (among MRSA) for strains isolated from participating units</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cost Effectiveness</title>
        <description>Cost effectiveness of routine care vs decolonization</description>
        <time_frame>21 months</time_frame>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>MRSA and VRE Clinical Cultures Among Patients With Devices</title>
        <description>Sub-population analysis: Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>MRSA and VRE Clinical Cultures Among Patients With Devices</title>
          <description>Sub-population analysis: Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
          <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15372"/>
                <count group_id="O2" value="23417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.00" upper_limit="1.37"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.69" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>MRSA Clinical Cultures Among Patients With Devices</title>
        <description>Sub-population analysis: Methicillin-resistant Staphylococcus aureus (MRSA) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>MRSA Clinical Cultures Among Patients With Devices</title>
          <description>Sub-population analysis: Methicillin-resistant Staphylococcus aureus (MRSA) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
          <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15372"/>
                <count group_id="O2" value="23417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.99" upper_limit="1.39"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.74" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0126</p_value>
            <p_value_desc>Remains significant after adjusting for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>VRE Clinical Cultures Among Patients With Devices</title>
        <description>Sub-population analysis: Vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>VRE Clinical Cultures Among Patients With Devices</title>
          <description>Sub-population analysis: Vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains).</description>
          <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15372"/>
                <count group_id="O2" value="23417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="0.85" upper_limit="1.86"/>
                    <measurement group_id="O2" value="0.58" lower_limit="0.44" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Remained significant after adjusting for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All-cause Bloodstream Infections Among Patients With Devices</title>
        <description>Sub-population analysis: All-cause bloodstream infections attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.</description>
        <time_frame>21 months</time_frame>
        <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Usual Care</title>
            <description>Routine policy for showering or bathing non-critical care patients</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Decolonization</title>
            <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Bloodstream Infections Among Patients With Devices</title>
          <description>Sub-population analysis: All-cause bloodstream infections attributable to participating units (defined as occurring &gt;2 days into a participating unit stay through 2 days following unit discharge), among patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.</description>
          <population>Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)</population>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15372"/>
                <count group_id="O2" value="23417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.96" upper_limit="1.33"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.70" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>Remained significant after adjusting for multiple comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Assessed if hazard ratio between intervention vs baseline periods differs between study groups, accounting for clustering within hospitals</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Intervention duration (21 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Usual Care</title>
          <description>Routine policy for showering or bathing non-critical care patients</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Decolonization</title>
          <description>Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Arm 2: Decolonization: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183013"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="183013"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Diffuse itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on trunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash, location unknown</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs, trunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on groin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs, face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs, groin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs, trunk, face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on limbs, trunk, groin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
              <event>
                <sub_title>Mild rash on neck, forehead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156889"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="183013"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Huang, Principal Investigator &amp; Medical Director of Epidemiology and Infection Prevention</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>949-824-5073</phone>
      <email>sshuang@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

